Objective To evaluate the risk of hyponatremia during therapy with antidepressant drugs, in particular by investigating whether there is a different risk profile depending on the class or single active principles. Methods A meta-analysis was performed including all studies in which the risk of hyponatremia in subjects with or without antidepressant treatment was assessed. An extensive Medline, Embase and Cochrane search was performed, to retrieve all studies published up to February 5th 2024, using the following words: hyponatremia and antidepressant. Results Of 409 retrieved articles, 10 studies satisfied the inclusion criteria encompassing a total of 1,026,870 patients with 89,403 hyponatremic subjects. Treatments with selective serotonin reuptake inhibitors (OR=3.31 [2.41;4.56], p<0.01), serotonin-noradrenaline reuptake inhibitors (OR=5.79 [1.27;26.49], p=0.02) and tricyclic antidepressants (OR=3.01 [1.27;7.14], p=0.01) were found to be significantly associated with an increased risk of hyponatremia, whereas treatment with noradrenaline and specific serotonergic antidepressants was not. A network meta-analysis indicated that treatments with venlafaxine (OR=5.99 [2.39;14.99], p<0.01), paroxetine (OR=4.93 [2.01;12.12], p<0.01), sertraline (OR=4.15 [1.98;8.70], p<0.01), citalopram (OR=3.49 [1.54;7.9], p<0.01), escitalopram (OR=3.49 [1.49;8.19], p<0.01), fluoxetine (OR=3.40 [1.13;10.21], p=0.03) and mirtazapine (OR=2.83 [1.16;6.92], p=0.02) were found to be significantly associated with an increased risk of hyponatremia with a progressively decreasing OR. Clomipramine (OR=4.50 [0.97;20.93], p=0.05) also showed a trend towards a greater risk of hyponatremia. Otherwise, treatments with fluvoxamine, imipramine, maprotiline, amitriptyline and mianserin were not associated with an increased risk of hyponatremia. Conclusions These data appear useful on clinical grounds, in order to increase the awareness regarding the possibility that antidepressants induce hyponatremia and to encourage regular serum sodium monitoring
Treatment with antidepressant drugs and hyponatremia: a network meta-analysis / Dario Norello, Giuseppe Defazio, Giovanni Corona, Chiara Caiulo, Mario Maggi, Alessandro Peri. - In: JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION. - ISSN 1720-8386. - STAMPA. - 48:(2025), pp. 1707-1715. [10.1007/s40618-025-02587-4]
Treatment with antidepressant drugs and hyponatremia: a network meta-analysis
Giuseppe Defazio;Mario Maggi;Alessandro Peri
2025
Abstract
Objective To evaluate the risk of hyponatremia during therapy with antidepressant drugs, in particular by investigating whether there is a different risk profile depending on the class or single active principles. Methods A meta-analysis was performed including all studies in which the risk of hyponatremia in subjects with or without antidepressant treatment was assessed. An extensive Medline, Embase and Cochrane search was performed, to retrieve all studies published up to February 5th 2024, using the following words: hyponatremia and antidepressant. Results Of 409 retrieved articles, 10 studies satisfied the inclusion criteria encompassing a total of 1,026,870 patients with 89,403 hyponatremic subjects. Treatments with selective serotonin reuptake inhibitors (OR=3.31 [2.41;4.56], p<0.01), serotonin-noradrenaline reuptake inhibitors (OR=5.79 [1.27;26.49], p=0.02) and tricyclic antidepressants (OR=3.01 [1.27;7.14], p=0.01) were found to be significantly associated with an increased risk of hyponatremia, whereas treatment with noradrenaline and specific serotonergic antidepressants was not. A network meta-analysis indicated that treatments with venlafaxine (OR=5.99 [2.39;14.99], p<0.01), paroxetine (OR=4.93 [2.01;12.12], p<0.01), sertraline (OR=4.15 [1.98;8.70], p<0.01), citalopram (OR=3.49 [1.54;7.9], p<0.01), escitalopram (OR=3.49 [1.49;8.19], p<0.01), fluoxetine (OR=3.40 [1.13;10.21], p=0.03) and mirtazapine (OR=2.83 [1.16;6.92], p=0.02) were found to be significantly associated with an increased risk of hyponatremia with a progressively decreasing OR. Clomipramine (OR=4.50 [0.97;20.93], p=0.05) also showed a trend towards a greater risk of hyponatremia. Otherwise, treatments with fluvoxamine, imipramine, maprotiline, amitriptyline and mianserin were not associated with an increased risk of hyponatremia. Conclusions These data appear useful on clinical grounds, in order to increase the awareness regarding the possibility that antidepressants induce hyponatremia and to encourage regular serum sodium monitoring| File | Dimensione | Formato | |
|---|---|---|---|
|
Antidepressants and hyponatremia.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Open Access
Dimensione
1.95 MB
Formato
Adobe PDF
|
1.95 MB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



